Wave Life Sciences (WVE) Assets (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Assets came in at $558.3 million in Q2 2026, up 121.24% YoY from $252.4 million in Q2 2025, and down 4.32% on a QoQ basis from $583.5 million in Q1 2026.
Wave Life Sciences (WVE) Assets (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Assets data on file, last reported at $558.3 million in Q2 2026.
- Quarterly Assets rose 121.24% year-over-year to $558.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $558.3 million (up 121.24% YoY) and the FY2025 annual result came in at $638.5 million, up 81.29% from the prior year.
- Assets eased to $558.3 million in Q2 2026, from $583.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $638.5 million in Q4 2025 to a low of $146.4 million in Q4 2022.
- A 5-year average of $299.9 million and a median of $246.9 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2025 — Assets plunged 32.67% — and 2026, when it jumped 121.24%.
- Tracing WVE's Assets over 5 years: stood at $146.4 million in 2022, then surged by 87.82% to $274.9 million in 2023, then climbed by 28.1% to $352.2 million in 2024, then soared by 81.29% to $638.5 million in 2025, then slipped by 12.56% to $558.3 million in 2026.
- The last three Assets figures came in at $558.3 million (Q2 2026), $583.5 million (Q1 2026), and $638.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 558.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 558.32 Mn |
| Mar 31, 2026 | 583.54 Mn |
| Dec 31, 2025 | 638.50 Mn |
| Sep 30, 2025 | 241.38 Mn |
| Jun 30, 2025 | 252.36 Mn |
| Mar 31, 2025 | 288.34 Mn |
| Dec 31, 2024 | 352.21 Mn |
| Sep 30, 2024 | 358.50 Mn |
| Jun 30, 2024 | 208.82 Mn |
| Mar 31, 2024 | 235.27 Mn |
| Dec 31, 2023 | 274.95 Mn |
| Sep 30, 2023 | 199.92 Mn |
| Jun 30, 2023 | 229.99 Mn |
| Mar 31, 2023 | 267.27 Mn |
| Dec 31, 2022 | 146.39 Mn |
| Sep 30, 2022 | 181.51 Mn |
| Jun 30, 2022 | 213.32 Mn |
| Mar 31, 2022 | 167.36 Mn |
| Dec 31, 2021 | 207.01 Mn |
| Sep 30, 2021 | 200.51 Mn |